Values First Advisors Inc. Increases Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Values First Advisors Inc. increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 20.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,725 shares of the company’s stock after acquiring an additional 3,971 shares during the quarter. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $925,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in Mirum Pharmaceuticals by 37.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after acquiring an additional 432,824 shares during the period. Silvercrest Asset Management Group LLC raised its holdings in Mirum Pharmaceuticals by 64.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock worth $4,090,000 after purchasing an additional 63,871 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in Mirum Pharmaceuticals by 6.9% in the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock worth $7,854,000 after purchasing an additional 14,843 shares in the last quarter. Candriam S.C.A. bought a new position in Mirum Pharmaceuticals in the second quarter worth $17,384,000. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in Mirum Pharmaceuticals by 64.9% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company’s stock worth $3,582,000 after purchasing an additional 41,236 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 2.4 %

Shares of NASDAQ:MIRM opened at $39.36 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $45.23. The company has a debt-to-equity ratio of 1.34, a quick ratio of 3.09 and a current ratio of 3.28. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -10.61 and a beta of 1.14. The stock’s 50-day simple moving average is $40.42 and its two-hundred day simple moving average is $34.12.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The company had revenue of $77.90 million for the quarter, compared to analysts’ expectations of $75.03 million. During the same period in the previous year, the firm earned ($0.92) earnings per share. The firm’s quarterly revenue was up 107.7% on a year-over-year basis. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of several analyst reports. Cantor Fitzgerald raised their price target on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Evercore ISI raised their price target on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Friday, October 11th. Finally, Leerink Partners lifted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $56.82.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.